世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

進行性核上性麻痺の世界市場成長(現状と展望)2024-2030年


Global Progressive Supranuclear Palsy Market Growth (Status and Outlook) 2024-2030

LPI(LPインフォメーション)の最新調査によると、世界の進行性核上性麻痺の市場規模は2023年に100万米ドルと評価されました。川下市場での需要の増加に伴い、進行性核上性麻痺はレビュー期間中のCAGR %で2030年... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2024年6月21日 US$3,660
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
105 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

LPI(LPインフォメーション)の最新調査によると、世界の進行性核上性麻痺の市場規模は2023年に100万米ドルと評価されました。川下市場での需要の増加に伴い、進行性核上性麻痺はレビュー期間中のCAGR %で2030年までに100万米ドルの再調整規模になると予測されています。
この調査レポートは、世界の進行性核上性麻痺市場の成長可能性を明らかにしています。進行性核上性麻痺は今後の市場で安定した成長を示すと予想される。しかし、進行性核上性麻痺の普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要です。市場関係者は、進行性核上性麻痺市場がもたらす莫大な機会を活用するために、研究開発に投資し、戦略的パートナーシップを構築し、進化する消費者の嗜好に合わせた製品を提供する必要があります。
進行性核上性麻痺は、運動、歩行や平衡感覚の制御、言語、嚥下、視覚、気分や行動、思考に影響を及ぼす神経変性疾患の一種である。
世界の医薬品市場は、2022年には1,475億ドルに達し、今後6年間のCAGRは5%で成長する。医薬品市場には化学医薬品と生物学的製剤がある。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が公衆衛生の新たなニーズに機敏に対応する必要性をさらに強調している。
主な特徴
進行性核上性麻痺市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。
市場規模と成長:この調査レポートは、進行性核上性麻痺市場の現在の規模と成長の概要を提供します。過去のデータ、タイプ別(初期段階、臨床試験など)の市場区分、地域別の内訳などが含まれます。
市場の促進要因と課題:政府規制、環境問題、技術の進歩、消費者の嗜好の変化など、進行性核上性麻痺市場の成長を促進する要因を特定・分析することができます。また、インフラストラクチャーの制限、射程距離への不安、高額な初期費用など、業界が直面する課題も明らかにすることができます。
競合情勢:この調査レポートは、進行性核上性麻痺市場における競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれています。また、新興企業や市場に与える潜在的な影響にもスポットを当てています。
技術開発:この調査レポートは、進行性核上性麻痺産業における最新の技術開発を掘り下げることができます。これには、進行性核上性麻痺技術の進歩、進行性核上性麻痺の新規参入企業、進行性核上性麻痺の新規投資、進行性核上性麻痺の将来を形作るその他のイノベーションが含まれます。
川下の事業者の好み:本レポートは、進行性核上性麻痺市場における顧客の購買行動と採用動向を明らかにすることができます。顧客の購買決定、進行性核上性麻痺製品の嗜好に影響を与える要因も含まれます。
政府の政策とインセンティブこの調査レポートは、政府の政策やインセンティブが進行性核上性麻痺市場に与える影響を分析しています。これには、規制の枠組み、補助金、税制優遇措置、進行性核上性麻痺市場の促進を目的としたその他の施策の評価が含まれます。また、市場成長促進におけるこれらの政策の有効性も評価します。
環境への影響と持続可能性当調査レポートでは、進行性核上性麻痺市場の環境への影響と持続可能性の側面を評価します。
市場予測と将来展望:実施した分析に基づき、調査レポートは進行性核上性麻痺産業の市場予測と展望を提供します。これには、市場規模、成長率、地域動向、技術進歩や政策展開に関する予測などが含まれます。
提言と機会本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられています。市場関係者が新たなトレンドを活用し、課題を克服し、進行性核上性麻痺市場の成長と発展に貢献するための潜在的な機会を強調しています。
市場の細分化
進行性核上性麻痺市場は、タイプ別と用途別に分類されます。2019-2030年の期間について、セグメント間の成長により、タイプ別、アプリケーション別の消費額の正確な計算と予測を提供します。
タイプ別セグメント
初期段階
臨床試験
後期段階
その他
用途別セグメント
病院
クリニック
研究機関
その他
本レポートは地域別にも市場を分割しています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、一次専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
メルク社
アトンファーマ
ブリストル・マイヤーズ スクイブ(BMS)
グラクソ・スミスクライン plc
ノバルティスAG
テバ・ファーマシューティカル・インダストリーズ社
ABサイエンス
アッヴィ社
アルツプロテクトSAS
コーティス・バイオサイエンシズ社
アコルダ・セラピューティクス社
バイオジェン社


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Progressive Supranuclear Palsy Market Size 2019-2030
2.1.2 Progressive Supranuclear Palsy Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Progressive Supranuclear Palsy Segment by Type
2.2.1 Early Stage
2.2.2 Clinical Trial
2.2.3 Late Stage
2.2.4 Others
2.3 Progressive Supranuclear Palsy Market Size by Type
2.3.1 Progressive Supranuclear Palsy Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Progressive Supranuclear Palsy Market Size Market Share by Type (2019-2024)
2.4 Progressive Supranuclear Palsy Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Research Institutes
2.4.4 Others
2.5 Progressive Supranuclear Palsy Market Size by Application
2.5.1 Progressive Supranuclear Palsy Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Progressive Supranuclear Palsy Market Size Market Share by Application (2019-2024)
3 Progressive Supranuclear Palsy Market Size by Player
3.1 Progressive Supranuclear Palsy Market Size Market Share by Players
3.1.1 Global Progressive Supranuclear Palsy Revenue by Players (2019-2024)
3.1.2 Global Progressive Supranuclear Palsy Revenue Market Share by Players (2019-2024)
3.2 Global Progressive Supranuclear Palsy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Progressive Supranuclear Palsy by Regions
4.1 Progressive Supranuclear Palsy Market Size by Regions (2019-2024)
4.2 Americas Progressive Supranuclear Palsy Market Size Growth (2019-2024)
4.3 APAC Progressive Supranuclear Palsy Market Size Growth (2019-2024)
4.4 Europe Progressive Supranuclear Palsy Market Size Growth (2019-2024)
4.5 Middle East & Africa Progressive Supranuclear Palsy Market Size Growth (2019-2024)
5 Americas
5.1 Americas Progressive Supranuclear Palsy Market Size by Country (2019-2024)
5.2 Americas Progressive Supranuclear Palsy Market Size by Type (2019-2024)
5.3 Americas Progressive Supranuclear Palsy Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Progressive Supranuclear Palsy Market Size by Region (2019-2024)
6.2 APAC Progressive Supranuclear Palsy Market Size by Type (2019-2024)
6.3 APAC Progressive Supranuclear Palsy Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Progressive Supranuclear Palsy by Country (2019-2024)
7.2 Europe Progressive Supranuclear Palsy Market Size by Type (2019-2024)
7.3 Europe Progressive Supranuclear Palsy Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Progressive Supranuclear Palsy by Region (2019-2024)
8.2 Middle East & Africa Progressive Supranuclear Palsy Market Size by Type (2019-2024)
8.3 Middle East & Africa Progressive Supranuclear Palsy Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Progressive Supranuclear Palsy Market Forecast
10.1 Global Progressive Supranuclear Palsy Forecast by Regions (2025-2030)
10.1.1 Global Progressive Supranuclear Palsy Forecast by Regions (2025-2030)
10.1.2 Americas Progressive Supranuclear Palsy Forecast
10.1.3 APAC Progressive Supranuclear Palsy Forecast
10.1.4 Europe Progressive Supranuclear Palsy Forecast
10.1.5 Middle East & Africa Progressive Supranuclear Palsy Forecast
10.2 Americas Progressive Supranuclear Palsy Forecast by Country (2025-2030)
10.2.1 United States Progressive Supranuclear Palsy Market Forecast
10.2.2 Canada Progressive Supranuclear Palsy Market Forecast
10.2.3 Mexico Progressive Supranuclear Palsy Market Forecast
10.2.4 Brazil Progressive Supranuclear Palsy Market Forecast
10.3 APAC Progressive Supranuclear Palsy Forecast by Region (2025-2030)
10.3.1 China Progressive Supranuclear Palsy Market Forecast
10.3.2 Japan Progressive Supranuclear Palsy Market Forecast
10.3.3 Korea Progressive Supranuclear Palsy Market Forecast
10.3.4 Southeast Asia Progressive Supranuclear Palsy Market Forecast
10.3.5 India Progressive Supranuclear Palsy Market Forecast
10.3.6 Australia Progressive Supranuclear Palsy Market Forecast
10.4 Europe Progressive Supranuclear Palsy Forecast by Country (2025-2030)
10.4.1 Germany Progressive Supranuclear Palsy Market Forecast
10.4.2 France Progressive Supranuclear Palsy Market Forecast
10.4.3 UK Progressive Supranuclear Palsy Market Forecast
10.4.4 Italy Progressive Supranuclear Palsy Market Forecast
10.4.5 Russia Progressive Supranuclear Palsy Market Forecast
10.5 Middle East & Africa Progressive Supranuclear Palsy Forecast by Region (2025-2030)
10.5.1 Egypt Progressive Supranuclear Palsy Market Forecast
10.5.2 South Africa Progressive Supranuclear Palsy Market Forecast
10.5.3 Israel Progressive Supranuclear Palsy Market Forecast
10.5.4 Turkey Progressive Supranuclear Palsy Market Forecast
10.5.5 GCC Countries Progressive Supranuclear Palsy Market Forecast
10.6 Global Progressive Supranuclear Palsy Forecast by Type (2025-2030)
10.7 Global Progressive Supranuclear Palsy Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Merck & Co., Inc.
11.1.1 Merck & Co., Inc. Company Information
11.1.2 Merck & Co., Inc. Progressive Supranuclear Palsy Product Offered
11.1.3 Merck & Co., Inc. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Merck & Co., Inc. Main Business Overview
11.1.5 Merck & Co., Inc. Latest Developments
11.2 Aton Pharma, Inc.
11.2.1 Aton Pharma, Inc. Company Information
11.2.2 Aton Pharma, Inc. Progressive Supranuclear Palsy Product Offered
11.2.3 Aton Pharma, Inc. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Aton Pharma, Inc. Main Business Overview
11.2.5 Aton Pharma, Inc. Latest Developments
11.3 Bristol Myers Squibb (BMS)
11.3.1 Bristol Myers Squibb (BMS) Company Information
11.3.2 Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Product Offered
11.3.3 Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Bristol Myers Squibb (BMS) Main Business Overview
11.3.5 Bristol Myers Squibb (BMS) Latest Developments
11.4 GlaxoSmithKline plc
11.4.1 GlaxoSmithKline plc Company Information
11.4.2 GlaxoSmithKline plc Progressive Supranuclear Palsy Product Offered
11.4.3 GlaxoSmithKline plc Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 GlaxoSmithKline plc Main Business Overview
11.4.5 GlaxoSmithKline plc Latest Developments
11.5 Novartis AG
11.5.1 Novartis AG Company Information
11.5.2 Novartis AG Progressive Supranuclear Palsy Product Offered
11.5.3 Novartis AG Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Novartis AG Main Business Overview
11.5.5 Novartis AG Latest Developments
11.6 Teva Pharmaceutical Industries Ltd.
11.6.1 Teva Pharmaceutical Industries Ltd. Company Information
11.6.2 Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Product Offered
11.6.3 Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
11.6.5 Teva Pharmaceutical Industries Ltd. Latest Developments
11.7 AB Science
11.7.1 AB Science Company Information
11.7.2 AB Science Progressive Supranuclear Palsy Product Offered
11.7.3 AB Science Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 AB Science Main Business Overview
11.7.5 AB Science Latest Developments
11.8 AbbVie Inc.
11.8.1 AbbVie Inc. Company Information
11.8.2 AbbVie Inc. Progressive Supranuclear Palsy Product Offered
11.8.3 AbbVie Inc. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 AbbVie Inc. Main Business Overview
11.8.5 AbbVie Inc. Latest Developments
11.9 AlzProtect SAS
11.9.1 AlzProtect SAS Company Information
11.9.2 AlzProtect SAS Progressive Supranuclear Palsy Product Offered
11.9.3 AlzProtect SAS Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 AlzProtect SAS Main Business Overview
11.9.5 AlzProtect SAS Latest Developments
11.10 Cortice Biosciences, Inc.
11.10.1 Cortice Biosciences, Inc. Company Information
11.10.2 Cortice Biosciences, Inc. Progressive Supranuclear Palsy Product Offered
11.10.3 Cortice Biosciences, Inc. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Cortice Biosciences, Inc. Main Business Overview
11.10.5 Cortice Biosciences, Inc. Latest Developments
11.11 Acorda Therapeutics Inc.
11.11.1 Acorda Therapeutics Inc. Company Information
11.11.2 Acorda Therapeutics Inc. Progressive Supranuclear Palsy Product Offered
11.11.3 Acorda Therapeutics Inc. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Acorda Therapeutics Inc. Main Business Overview
11.11.5 Acorda Therapeutics Inc. Latest Developments
11.12 Biogen Inc.
11.12.1 Biogen Inc. Company Information
11.12.2 Biogen Inc. Progressive Supranuclear Palsy Product Offered
11.12.3 Biogen Inc. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Biogen Inc. Main Business Overview
11.12.5 Biogen Inc. Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

According to our LPI (LP Information) latest study, the global Progressive Supranuclear Palsy market size was valued at US$ million in 2023. With growing demand in downstream market, the Progressive Supranuclear Palsy is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Progressive Supranuclear Palsy market. Progressive Supranuclear Palsy are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Progressive Supranuclear Palsy. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Progressive Supranuclear Palsy market.
Progressive Supranuclear Palsy is a class of neuro-degenerative disorder that affects movement, control of walking and balance, speech, swallowing, vision, mood and behavior, and thinking.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Progressive Supranuclear Palsy market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Progressive Supranuclear Palsy market. It may include historical data, market segmentation by Type (e.g., Early Stage, Clinical Trial), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Progressive Supranuclear Palsy market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Progressive Supranuclear Palsy market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Progressive Supranuclear Palsy industry. This include advancements in Progressive Supranuclear Palsy technology, Progressive Supranuclear Palsy new entrants, Progressive Supranuclear Palsy new investment, and other innovations that are shaping the future of Progressive Supranuclear Palsy.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Progressive Supranuclear Palsy market. It includes factors influencing customer ' purchasing decisions, preferences for Progressive Supranuclear Palsy product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Progressive Supranuclear Palsy market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Progressive Supranuclear Palsy market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Progressive Supranuclear Palsy market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Progressive Supranuclear Palsy industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Progressive Supranuclear Palsy market.
Market Segmentation:
Progressive Supranuclear Palsy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Early Stage
Clinical Trial
Late Stage
Others
Segmentation by application
Hospitals
Clinics
Research Institutes
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck & Co., Inc.
Aton Pharma, Inc.
Bristol Myers Squibb (BMS)
GlaxoSmithKline plc
Novartis AG
Teva Pharmaceutical Industries Ltd.
AB Science
AbbVie Inc.
AlzProtect SAS
Cortice Biosciences, Inc.
Acorda Therapeutics Inc.
Biogen Inc.



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Progressive Supranuclear Palsy Market Size 2019-2030
2.1.2 Progressive Supranuclear Palsy Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Progressive Supranuclear Palsy Segment by Type
2.2.1 Early Stage
2.2.2 Clinical Trial
2.2.3 Late Stage
2.2.4 Others
2.3 Progressive Supranuclear Palsy Market Size by Type
2.3.1 Progressive Supranuclear Palsy Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Progressive Supranuclear Palsy Market Size Market Share by Type (2019-2024)
2.4 Progressive Supranuclear Palsy Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Research Institutes
2.4.4 Others
2.5 Progressive Supranuclear Palsy Market Size by Application
2.5.1 Progressive Supranuclear Palsy Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Progressive Supranuclear Palsy Market Size Market Share by Application (2019-2024)
3 Progressive Supranuclear Palsy Market Size by Player
3.1 Progressive Supranuclear Palsy Market Size Market Share by Players
3.1.1 Global Progressive Supranuclear Palsy Revenue by Players (2019-2024)
3.1.2 Global Progressive Supranuclear Palsy Revenue Market Share by Players (2019-2024)
3.2 Global Progressive Supranuclear Palsy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Progressive Supranuclear Palsy by Regions
4.1 Progressive Supranuclear Palsy Market Size by Regions (2019-2024)
4.2 Americas Progressive Supranuclear Palsy Market Size Growth (2019-2024)
4.3 APAC Progressive Supranuclear Palsy Market Size Growth (2019-2024)
4.4 Europe Progressive Supranuclear Palsy Market Size Growth (2019-2024)
4.5 Middle East & Africa Progressive Supranuclear Palsy Market Size Growth (2019-2024)
5 Americas
5.1 Americas Progressive Supranuclear Palsy Market Size by Country (2019-2024)
5.2 Americas Progressive Supranuclear Palsy Market Size by Type (2019-2024)
5.3 Americas Progressive Supranuclear Palsy Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Progressive Supranuclear Palsy Market Size by Region (2019-2024)
6.2 APAC Progressive Supranuclear Palsy Market Size by Type (2019-2024)
6.3 APAC Progressive Supranuclear Palsy Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Progressive Supranuclear Palsy by Country (2019-2024)
7.2 Europe Progressive Supranuclear Palsy Market Size by Type (2019-2024)
7.3 Europe Progressive Supranuclear Palsy Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Progressive Supranuclear Palsy by Region (2019-2024)
8.2 Middle East & Africa Progressive Supranuclear Palsy Market Size by Type (2019-2024)
8.3 Middle East & Africa Progressive Supranuclear Palsy Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Progressive Supranuclear Palsy Market Forecast
10.1 Global Progressive Supranuclear Palsy Forecast by Regions (2025-2030)
10.1.1 Global Progressive Supranuclear Palsy Forecast by Regions (2025-2030)
10.1.2 Americas Progressive Supranuclear Palsy Forecast
10.1.3 APAC Progressive Supranuclear Palsy Forecast
10.1.4 Europe Progressive Supranuclear Palsy Forecast
10.1.5 Middle East & Africa Progressive Supranuclear Palsy Forecast
10.2 Americas Progressive Supranuclear Palsy Forecast by Country (2025-2030)
10.2.1 United States Progressive Supranuclear Palsy Market Forecast
10.2.2 Canada Progressive Supranuclear Palsy Market Forecast
10.2.3 Mexico Progressive Supranuclear Palsy Market Forecast
10.2.4 Brazil Progressive Supranuclear Palsy Market Forecast
10.3 APAC Progressive Supranuclear Palsy Forecast by Region (2025-2030)
10.3.1 China Progressive Supranuclear Palsy Market Forecast
10.3.2 Japan Progressive Supranuclear Palsy Market Forecast
10.3.3 Korea Progressive Supranuclear Palsy Market Forecast
10.3.4 Southeast Asia Progressive Supranuclear Palsy Market Forecast
10.3.5 India Progressive Supranuclear Palsy Market Forecast
10.3.6 Australia Progressive Supranuclear Palsy Market Forecast
10.4 Europe Progressive Supranuclear Palsy Forecast by Country (2025-2030)
10.4.1 Germany Progressive Supranuclear Palsy Market Forecast
10.4.2 France Progressive Supranuclear Palsy Market Forecast
10.4.3 UK Progressive Supranuclear Palsy Market Forecast
10.4.4 Italy Progressive Supranuclear Palsy Market Forecast
10.4.5 Russia Progressive Supranuclear Palsy Market Forecast
10.5 Middle East & Africa Progressive Supranuclear Palsy Forecast by Region (2025-2030)
10.5.1 Egypt Progressive Supranuclear Palsy Market Forecast
10.5.2 South Africa Progressive Supranuclear Palsy Market Forecast
10.5.3 Israel Progressive Supranuclear Palsy Market Forecast
10.5.4 Turkey Progressive Supranuclear Palsy Market Forecast
10.5.5 GCC Countries Progressive Supranuclear Palsy Market Forecast
10.6 Global Progressive Supranuclear Palsy Forecast by Type (2025-2030)
10.7 Global Progressive Supranuclear Palsy Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Merck & Co., Inc.
11.1.1 Merck & Co., Inc. Company Information
11.1.2 Merck & Co., Inc. Progressive Supranuclear Palsy Product Offered
11.1.3 Merck & Co., Inc. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Merck & Co., Inc. Main Business Overview
11.1.5 Merck & Co., Inc. Latest Developments
11.2 Aton Pharma, Inc.
11.2.1 Aton Pharma, Inc. Company Information
11.2.2 Aton Pharma, Inc. Progressive Supranuclear Palsy Product Offered
11.2.3 Aton Pharma, Inc. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Aton Pharma, Inc. Main Business Overview
11.2.5 Aton Pharma, Inc. Latest Developments
11.3 Bristol Myers Squibb (BMS)
11.3.1 Bristol Myers Squibb (BMS) Company Information
11.3.2 Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Product Offered
11.3.3 Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Bristol Myers Squibb (BMS) Main Business Overview
11.3.5 Bristol Myers Squibb (BMS) Latest Developments
11.4 GlaxoSmithKline plc
11.4.1 GlaxoSmithKline plc Company Information
11.4.2 GlaxoSmithKline plc Progressive Supranuclear Palsy Product Offered
11.4.3 GlaxoSmithKline plc Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 GlaxoSmithKline plc Main Business Overview
11.4.5 GlaxoSmithKline plc Latest Developments
11.5 Novartis AG
11.5.1 Novartis AG Company Information
11.5.2 Novartis AG Progressive Supranuclear Palsy Product Offered
11.5.3 Novartis AG Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Novartis AG Main Business Overview
11.5.5 Novartis AG Latest Developments
11.6 Teva Pharmaceutical Industries Ltd.
11.6.1 Teva Pharmaceutical Industries Ltd. Company Information
11.6.2 Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Product Offered
11.6.3 Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
11.6.5 Teva Pharmaceutical Industries Ltd. Latest Developments
11.7 AB Science
11.7.1 AB Science Company Information
11.7.2 AB Science Progressive Supranuclear Palsy Product Offered
11.7.3 AB Science Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 AB Science Main Business Overview
11.7.5 AB Science Latest Developments
11.8 AbbVie Inc.
11.8.1 AbbVie Inc. Company Information
11.8.2 AbbVie Inc. Progressive Supranuclear Palsy Product Offered
11.8.3 AbbVie Inc. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 AbbVie Inc. Main Business Overview
11.8.5 AbbVie Inc. Latest Developments
11.9 AlzProtect SAS
11.9.1 AlzProtect SAS Company Information
11.9.2 AlzProtect SAS Progressive Supranuclear Palsy Product Offered
11.9.3 AlzProtect SAS Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 AlzProtect SAS Main Business Overview
11.9.5 AlzProtect SAS Latest Developments
11.10 Cortice Biosciences, Inc.
11.10.1 Cortice Biosciences, Inc. Company Information
11.10.2 Cortice Biosciences, Inc. Progressive Supranuclear Palsy Product Offered
11.10.3 Cortice Biosciences, Inc. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Cortice Biosciences, Inc. Main Business Overview
11.10.5 Cortice Biosciences, Inc. Latest Developments
11.11 Acorda Therapeutics Inc.
11.11.1 Acorda Therapeutics Inc. Company Information
11.11.2 Acorda Therapeutics Inc. Progressive Supranuclear Palsy Product Offered
11.11.3 Acorda Therapeutics Inc. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Acorda Therapeutics Inc. Main Business Overview
11.11.5 Acorda Therapeutics Inc. Latest Developments
11.12 Biogen Inc.
11.12.1 Biogen Inc. Company Information
11.12.2 Biogen Inc. Progressive Supranuclear Palsy Product Offered
11.12.3 Biogen Inc. Progressive Supranuclear Palsy Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Biogen Inc. Main Business Overview
11.12.5 Biogen Inc. Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/09/20 10:26

143.76 円

160.81 円

193.57 円

ページTOPに戻る